gemifloxacin has been researched along with Breast-Neoplasms* in 3 studies
3 other study(ies) available for gemifloxacin and Breast-Neoplasms
Article | Year |
---|---|
Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.
Gemifloxacin (GMF) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. The aim of this study was to investigate the anti-metastatic activities of GMF and its possible mechanisms of action, with a special focus on the induction of mesenchymal-epithelial transition (MET). The human breast adenocarcinoma cell lines MDA-MB-231 and MDA-MB-453 were used to assess the anti-metastatic activity of GMF on cell migration and invasion and in scratch wound-healing assays. The effects of GMF on the MET and its regulatory nuclear factor κB (NF-κB)/Snail pathway were assessed. The in vivo anti-metastatic effect of GMF was also evaluated in an animal model. This study demonstrated that GMF inhibited the migration and invasion of MDA-MB-231 and MDA-MB-453 cells and induced the MET. GMF suppressed the activation of NF-κB, as well as the cell migration and invasion induced by tumor necrosis factor α (TNF-α). GMF was shown to inhibit the phosphorylation of the inhibitor of κB (IκB) and the translocation of NF-κB/Snail in both cancer cell lines. This study showed that the Raf kinase inhibitor protein (RKIP), an inhibitor of IκB kinase, is upregulated after GMF treatment. Inhibition of RKIP by small hairpin RNA transfection significantly decreased the inhibitory effect of GMF on the NF-κB/Snail pathway and also inhibited cell migration and invasion. Overexpression of Snail suppressed GMF-mediated metastasis inhibition and E-cadherin upregulation. An animal model revealed that GMF effectively inhibits lipopolysaccharide-mediated metastasis in mice. This study has demonstrated that GMF might be a novel anticancer agent for the prevention and treatment of metastasis in breast cancer.. GMF inhibits the migration and invasion of human breast adenocarcinoma cells. GMF induces MET by reducing NF-κB and Snail activation and by increasing RKIP levels. GMF has potential clinical implication as an anti-metastatic agent for breast cancer. Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Epithelial-Mesenchymal Transition; Female; Fluoroquinolones; Gemifloxacin; Gene Expression Regulation, Neoplastic; Humans; Mice; Naphthyridines; Neoplasm Metastasis; NF-kappa B; Phosphatidylethanolamine Binding Protein; Signal Transduction; Snail Family Transcription Factors; Topoisomerase II Inhibitors; Transcription Factors; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2014 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
A facile synthesis of model 4-oxopyrido[3',2':4,5]thieno[3,2-b]indole-3-carboxylic acids 9a-e was achieved via Stille arylation of 2-chloro-3-nitro-4-oxothieno[2,3-b]pyridine-5-carboxylate and a subsequent microwave-assisted phosphite-mediated Cadogan reaction. The new compounds were tested for their in vitro antimicrobial and antiproliferative activity. Compounds 9a-c and 9e exhibited very high potency against Gram positive Bacillus subtilis and Bacillus megaterium at concentrations 0.000015-0.007 μg/mL. They also displayed excellent activity towards other Gram positive bacilli and staphylococci and Gram negative Haemophilus influenzae, being in most cases superior or equal to commercial fluoroquinolones. Both 9a and 9c were inhibitors of the DNA gyrase activity. As concerns antitumor properties, compounds 9b-e showed growth inhibition of MCF-7 breast tumor and A549 non-small cell lung cancer cells with IC(50) 1.6-2.8 μM and 2.6-6.9 μM, respectively, coupled with absence of cytotoxicity towards normal cells. These compounds are promising as dual acting chemotherapeutics. Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
A simple and efficient synthesis of 6-fluoro-4-oxopyrido[2,3-a]carbazole-3-carboxylic acids (13a-e) and a structurally related 6-fluoro-4-oxothieno[2',3':4,5]pyrrolo[3,2-h]quinoline (13f) was achieved via Stille arylation of 7-chloro-6-fluoro-8-nitro-4-oxoquinoline-3-carboxylate and a subsequent microwave-assisted phosphite-mediated Cadogan reaction. The new compounds were tested for their in vitro antimicrobial and antiproliferative activity. The ability of 13a-f to inhibit the activity of DNA gyrase and topoisomerase IV was also investigated. The thieno isostere (13f) emerged as the most active antibacterial, while the 9-fluoro derivative (13e) was the most potent against multidrug-resistant staphylococci. Compounds 13a, 13c-f displayed growth inhibition against MCF-7 breast tumor and A549 non-small cell lung cancer cells coupled with an absence of cytotoxicity toward normal human-derm fibroblasts (HuDe). Compound 13e was the most active anticancer against MCF-7 cells, with greater potency than ellipticine (IC(50) 0.8 and 1.6muM, respectively). The most active compounds in this series show promise as dual acting anticancer and antibacterial chemotherapeutics. Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |